Markets are tanking on tariff fears, inflationary concerns and now fears of recession. "Given this is so uncertain and that ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 7,265 contracts has been ...

Here are three reasons why BIIB doesn't excite us and a stock we'd rather own. Founded in 1978 in Switzerland as one of the ...

High-rolling investors have positioned themselves bullish on Biogen (NASDAQ:BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders purchased 32,455 put options on the company. This represents an increase of ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Jones Financial Companies Lllp boosted its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.2% in the 4th quarter, ...

Shares of oversold pharmaceutical giant Biogen (NASDAQ:BIIB) are up about $4.40 on the day. While we’re not seeing any specific news for the pivot higher, BIIB has become a value play.